Condition
T-cell Lymphoma Adults
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06149390CompletedPrimary
ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma
NCT03207789Unknown
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
NCT01788137Phase 3UnknownPrimary
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
Showing all 3 trials